MADDEN SECURITIES Corp Has $470,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

MADDEN SECURITIES Corp trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 854 shares of the medical research company’s stock after selling 25 shares during the period. MADDEN SECURITIES Corp’s holdings in Thermo Fisher Scientific were worth $470,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Grayhawk Investment Strategies Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $26,000. Lowe Wealth Advisors LLC increased its position in Thermo Fisher Scientific by 160.0% during the third quarter. Lowe Wealth Advisors LLC now owns 52 shares of the medical research company’s stock worth $26,000 after buying an additional 32 shares during the last quarter. New Millennium Group LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth approximately $29,000. Toth Financial Advisory Corp increased its position in Thermo Fisher Scientific by 7,300.0% during the third quarter. Toth Financial Advisory Corp now owns 74 shares of the medical research company’s stock worth $38,000 after buying an additional 73 shares during the last quarter. Finally, Coston McIsaac & Partners acquired a new position in Thermo Fisher Scientific during the second quarter worth approximately $44,000. 85.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on TMO shares. Citigroup upped their target price on Thermo Fisher Scientific from $650.00 to $700.00 and gave the company a “buy” rating in a research report on Thursday, February 2nd. Deutsche Bank Aktiengesellschaft initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, December 13th. They set a “buy” rating and a $620.00 target price for the company. SVB Leerink upped their target price on Thermo Fisher Scientific from $620.00 to $630.00 and gave the stock an “outperform” rating in a research note on Thursday, February 2nd. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Morgan Stanley increased their price target on Thermo Fisher Scientific from $613.00 to $670.00 and gave the company an “overweight” rating in a research note on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $647.00.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $9.75 during mid-day trading on Friday, reaching $547.34. 1,947,936 shares of the stock traded hands, compared to its average volume of 1,498,879. The firm has a fifty day moving average price of $565.91 and a 200 day moving average price of $545.06. The company has a market cap of $210.96 billion, a price-to-earnings ratio of 31.05, a price-to-earnings-growth ratio of 1.88 and a beta of 0.79. The company has a current ratio of 1.48, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 1 year low of $475.77 and a 1 year high of $618.35.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its earnings results on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.19 by $0.21. The company had revenue of $11.45 billion during the quarter, compared to analyst estimates of $10.41 billion. Thermo Fisher Scientific had a net margin of 15.47% and a return on equity of 21.42%. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $6.54 earnings per share. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.72 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 14th. Stockholders of record on Wednesday, March 15th will be paid a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a dividend yield of 0.26%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. The ex-dividend date is Tuesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 7.94%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $569.18, for a total value of $11,383,600.00. Following the sale, the chief executive officer now owns 128,705 shares in the company, valued at $73,256,311.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $584.56, for a total value of $584,560.00. Following the transaction, the director now directly owns 14,807 shares of the company’s stock, valued at approximately $8,655,579.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction on Friday, February 10th. The stock was sold at an average price of $569.18, for a total value of $11,383,600.00. Following the completion of the transaction, the chief executive officer now directly owns 128,705 shares in the company, valued at $73,256,311.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,100 shares of company stock valued at $16,966,971. Insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.